Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

Area of Science:

• Immunology
• Virology
• Vaccine Development

Background:

• Influenza virus evolution necessitates frequent vaccine reformulation.
• Conserved antigens offer a promising strategy for broader vaccine protection.
• Influenza matrix protein 2 (M2) is highly conserved across influenza A subtypes.

Purpose of the Study:

• To evaluate the efficacy of M2 protein as a vaccine candidate for broad influenza A protection.
• To assess the immunogenicity and protective capabilities of M2-based vaccines in a mouse model.

Main Methods:

• Mice were vaccinated with M2 peptides and M2-DNA vaccines.
• A prime-boost strategy using M2-DNA followed by M2-adenovirus was employed.
• Vaccine efficacy was assessed by antibody cross-reactivity and protection against lethal influenza challenge, including H5N1.

Main Results:

• M2 peptide vaccination induced cross-reactive antibodies against divergent M2 subtypes.
• M2-DNA vaccination elicited M2-specific antibodies and protected mice from lethal influenza.
• M2 prime-boost vaccination enhanced antibody responses, including cross-reactivity with human and avian M2, and induced T-cell responses.
• This prime-boost strategy conferred broad protection against lethal influenza A challenge, including an H5N1 strain.

Conclusions:

• Vaccination targeting conserved sequences of influenza M2 protein can elicit broadly protective immune responses.
• M2-based vaccines, particularly using a prime-boost approach, show potential for developing universal influenza A vaccines.
• Further development of M2-targeting vaccines may offer a viable strategy against diverse and potentially pandemic influenza A strains.